Sander13677 schreef op 24 oktober 2023 07:57:
Pharming Group NV is expected to show a rise in quarterly revenue when it reports results
The Leiden Zuid-holland-based company is expected to report a 13.1% increase in revenue to $61.34 million from $54.24 million a year ago, according to the estimate from one analyst, based on Refinitiv data.
?Refinitiv's mean analyst estimate for Pharming Group NV is for a loss of 3 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months. ?
Wall Street's median 12-month price target for Pharming Group NV is €1.9?, below? its last closing price of $10.19. ???
This summary was machine generated October 24 at 05:02 GMT. All figures in US dollars unless otherwise stated.